FDA is­sues rare no­tice of non­com­pli­ance for not re­port­ing clin­i­cal tri­al re­sults

In a rare move, the FDA is­sued a no­tice of non­com­pli­ance to an on­col­o­gy com­pa­ny for fail­ing to sub­mit clin­i­cal da­ta on its treat­ment for be­nign pro­sta­t­ic hy­per­pla­sia to a fed­er­al data­base.

Un­der the Food and Drug Ad­min­is­tra­tion Amend­ments Act of 2007, spon­sors are re­quired to sub­mit cer­tain re­sults from clin­i­cal tri­als to Clin­i­cal­Tri­als.gov, gen­er­al­ly no lat­er than one year af­ter com­ple­tion of the tri­al. They can be grant­ed an ex­ten­sion if they sub­mit a re­quest for a de­lay in post­ing the da­ta, though the re­quest must be sub­mit­ted by a cer­tain dead­line.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER